No Data
Microtech Medical-B (02235.HK) spent 0.2128 million Hong Kong dollars to repurchase 0.0361 million shares on January 2.
Gelonghui, January 2nd丨Weitai Medical-B (02235.HK) announced that on January 2, 2025, it spent 0.2128 million Hong Kong dollars to repurchase 0.0361 million shares, with a repurchase price per share ranging from 5.81 to 5.96 Hong Kong dollars.
Wei Tai Medical-B (02235) spent HKD 3.6532 million to repurchase 0.609 million shares on December 31.
MicroTech Medical-B (02235) announced that on December 31, 2024, the company will invest 365.32...
On December 30, Weitai Medical-B (02235.HK) spent 0.957 million Hong Kong dollars to repurchase 0.16 million shares.
On December 30, Gelonghui announced that Weitai Medical-B (02235.HK) spent 0.957 million Hong Kong dollars to buy back 0.16 million shares, with a repurchase price of 5.9-6 Hong Kong dollars per share.
Minsheng Securities: The advantages of CGM real-time blood glucose monitoring are significant, with outstanding clinical value.
Driven by factors such as the deepening global aging population, the increasing demand for the diagnosis and treatment of diabetes patients, and the gradual improvement of the healthcare insurance system, the CGM industry will experience continuous growth.
MicroTech Medical-B (02235.HK) spent 0.1293 million Hong Kong dollars to repurchase 0.0223 million shares on December 24.
Glonghui announced on December 24 that Weitai Medical-B (02235.HK) spent HKD 0.1293 million to repurchase 0.0223 million shares on December 24, with a repurchase price of HKD 5.72-5.8 per share.
On December 20, 2023, MicroTech Medical-B (02235.HK) spent 0.293 million Hong Kong dollars to repurchase 0.0537 million shares.
Gelonghui reported on December 20 that Weitai Medical-B (02235.HK) announced that it spent 0.293 million Hong Kong dollars to repurchase 0.0537 million shares on December 20.
